626 related articles for article (PubMed ID: 22982890)
1. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.
Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI
Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890
[TBL] [Abstract][Full Text] [Related]
2. GATA3 immunohistochemical expression in invasive urothelial carcinoma.
Mohammed KH; Siddiqui MT; Cohen C
Urol Oncol; 2016 Oct; 34(10):432.e9-432.e13. PubMed ID: 27241168
[TBL] [Abstract][Full Text] [Related]
3. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas.
Zhao L; Antic T; Witten D; Paner GP; Taxy JB; Husain A; Gwin K; Mirza MK; Lingen MW; Tretiakova MS
Am J Surg Pathol; 2013 Dec; 37(12):1876-81. PubMed ID: 24121175
[TBL] [Abstract][Full Text] [Related]
4. GATA3 expression in metastatic urothelial carcinoma in fine needle aspiration cell blocks: a review of 25 cases.
Siddiqui MT; Seydafkan S; Cohen C
Diagn Cytopathol; 2014 Sep; 42(9):809-15. PubMed ID: 24578300
[TBL] [Abstract][Full Text] [Related]
5. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
6. Utility of uroplakin II expression as a marker of urothelial carcinoma.
Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
[TBL] [Abstract][Full Text] [Related]
7. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung.
Gruver AM; Amin MB; Luthringer DJ; Westfall D; Arora K; Farver CF; Osunkoya AO; McKenney JK; Hansel DE
Arch Pathol Lab Med; 2012 Nov; 136(11):1339-46. PubMed ID: 23106579
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of GATA3 and p40 immunostains in the diagnosis of metastatic urothelial carcinoma in cytology specimens.
Brandler TC; Aziz MS; Rosen LM; Bhuiya TA; Yaskiv O
Cancer Cytopathol; 2014 Jun; 122(6):468-73. PubMed ID: 24711443
[TBL] [Abstract][Full Text] [Related]
9. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K
Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract.
Gulmann C; Paner GP; Parakh RS; Hansel DE; Shen SS; Ro JY; Annaiah C; Lopez-Beltran A; Rao P; Arora K; Cho Y; Herrera-Hernandez L; Alsabeh R; Amin MB
Hum Pathol; 2013 Feb; 44(2):164-72. PubMed ID: 22995333
[TBL] [Abstract][Full Text] [Related]
13. GATA3 expression in benign prostate glands with radiation atypia: a diagnostic pitfall.
Tian W; Dorn D; Wei S; Sanders RD; Matoso A; Shah RB; Gordetsky J
Histopathology; 2017 Jul; 71(1):150-155. PubMed ID: 28316088
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry for the novel markers glypican 3, PAX8, and p40 (ΔNp63) in squamous cell and urothelial carcinoma.
Gailey MP; Bellizzi AM
Am J Clin Pathol; 2013 Dec; 140(6):872-80. PubMed ID: 24225756
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical profile of the penile urethra and differential expression of GATA3 in urothelial versus squamous cell carcinomas of the penile urethra.
Chaux A; Han JS; Lee S; Gonzalez-Roibon N; Sharma R; Burnett AL; Cubilla AL; Netto GJ
Hum Pathol; 2013 Dec; 44(12):2760-7. PubMed ID: 24134931
[TBL] [Abstract][Full Text] [Related]
16. Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer.
Gaisa NT; Braunschweig T; Reimer N; Bornemann J; Eltze E; Siegert S; Toma M; Villa L; Hartmann A; Knuechel R
Virchows Arch; 2011 Mar; 458(3):301-12. PubMed ID: 21136076
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall.
Lobo J; Tenace NP; Cañete-Portillo S; Carneiro I; Henrique R; Lucianò R; Harik LR; Magi-Galluzzi C
Histopathology; 2024 Feb; 84(3):507-514. PubMed ID: 37965687
[TBL] [Abstract][Full Text] [Related]
18. Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the Differential Diagnosis of Invasive Urothelial Carcinoma.
Hoang LL; Tacha D; Bremer RE; Haas TS; Cheng L
Appl Immunohistochem Mol Morphol; 2015; 23(10):711-6. PubMed ID: 25611245
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of GATA-3 in urothelial carcinoma variants.
Liang Y; Heitzman J; Kamat AM; Dinney CP; Czerniak B; Guo CC
Hum Pathol; 2014 Jul; 45(7):1466-72. PubMed ID: 24745616
[TBL] [Abstract][Full Text] [Related]
20. GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin.
Bezerra SM; Lotan TL; Faraj SF; Karram S; Sharma R; Schoenberg M; Bivalacqua TJ; Netto GJ
Hum Pathol; 2014 Aug; 45(8):1682-7. PubMed ID: 24925221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
